For the year ending 2026-01-02, EXEL has $2,844,423K in assets. $683,104K in debts. $482,488K in cash and cash equivalents.
| Balance Sheets | 2026-01-02 | 2025-01-03 | 2023-12-29 | 2022-12-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 482,488 | 217,374 | 262,994 | 501,195 |
| Short-term investments | - | - | 732,308 | 807,273 |
| Marketable securities | 576,603 | 893,902 | - | - |
| Trade receivables, net | 286,916 | 265,437 | 237,407 | 214,784 |
| Inventory | 21,686 | 22,388 | 17,323 | 33,299 |
| Prepaid expenses and other current assets | 75,596 | 68,478 | 67,926 | 62,211 |
| Total current assets | 1,443,289 | 1,467,579 | 1,317,958 | 1,618,762 |
| Non-current marketable securities | 603,603 | 637,291 | - | - |
| Property and equipment, net | 98,960 | 119,391 | 128,731 | 110,624 |
| Long-term investments | - | - | 728,717 | 756,731 |
| Deferred tax assets, net | 292,582 | 420,027 | 361,145 | 231,110 |
| Goodwill | 63,684 | 63,684 | 63,684 | 63,684 |
| Right-of-use assets and other | - | - | 342,122 | 290,578 |
| Right-of-use assets and other non-current assets | 342,305 | 239,718 | - | - |
| Total assets | 2,844,423 | 2,947,690 | 2,942,357 | 3,071,489 |
| Accounts payable | 29,623 | 38,191 | 33,768 | 32,667 |
| Accrued compensation and benefits | 102,218 | 109,830 | 93,325 | 77,158 |
| Accrued clinical trial liabilities | 65,742 | 57,976 | 71,615 | 65,072 |
| Rebates and fees due to customers | 59,896 | 62,376 | 59,619 | 50,350 |
| Accrued collaboration liabilities | 22,783 | 40,384 | 27,533 | 20,188 |
| Other current liabilities | 125,382 | 95,012 | 108,417 | 78,924 |
| Total current liabilities | 405,644 | 403,769 | 394,277 | 324,359 |
| Non-current operating lease liabilities | 173,038 | 190,823 | 189,944 | 190,170 |
| Long-term portion of deferred revenue | - | - | - | 6,582 |
| Other non-current liabilities | 104,422 | 108,895 | 94,224 | 61,951 |
| Total liabilities | 683,104 | 703,487 | 678,445 | 583,062 |
| Common stock, 0.001 par value 400,000 shares authorized issued and outstanding 262,483 and 281,732 at december31, 2025 and 2024, respectively | 262 | 282 | 303 | 324 |
| Additional paid-in-capital | 2,234,411 | 2,343,915 | 2,440,710 | 2,536,849 |
| Accumulated other comprehensive income (loss) | 3,476 | -1,347 | -3,750 | -14,521 |
| Accumulated deficit | -76,830 | -98,647 | -173,351 | -34,225 |
| Total stockholders equity | 2,161,319 | 2,244,203 | 2,263,912 | 2,488,427 |
| Total liabilities and stockholders equity | 2,844,423 | 2,947,690 | 2,942,357 | 3,071,489 |
EXELIXIS, INC. (EXEL)
EXELIXIS, INC. (EXEL)